Reig Jofre, CataloniaBio & HealthTech member, has acquired Bioiberica’s portfolio of finished pharmaceutical and nutraceutical products, representing a turnover of € 26 million.
The pharmaceutical group managed by Ignasi Biosca is focussing on a new therapeutic area, Joint Health and Pain.
Osteoarticular disease is one of the most prevalent physical complaints in the world. It is estimated that between 5% and 20% of the population suffers from such afflictions, a figure that reaches around 80% in people aged over 65 in industrialized countries.
The operation also includes the incorporation of a team consisting of 51 people from the areas of R&D, regulatory, marketing, market access and commercial medical visits network, and an agreement by virtue of which Bioiberica will continue to produce the APIs and ingredients necessary for the manufacture of the portfolio sold to Reig Jofre.
Photo: from left to right, Gabriel Roig and Ignasi Biosca, in representation of Reig Jofre, and Luis Solera and Jordi Vidal of Bioiberica - © Reig Jofre
Comments